ArticleBrain and behavior2025
Evaluation of Prognostic Implication of Serum Mixed Lineage Kinase Domain-Like Protein in Acute Primary Supratentorial Intracerebral Hemorrhage: A Multicenter Prospective Cohort Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Practicability of Activating Transcription Factor 3 as a Serological Marker for Severity Appraisal and Outcome Anticipation in Acute Supratentorial Intracerebral Hemorrhage: A Two-center Observational Analytical Study.Brain and behavior · 2025Observational
- Serum P2X7 as a prognostic biomarker in acute supratentorial intracerebral hemorrhage: a two-center observational study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveMixed lineage kinase domain-like protein (MLKL) is a key component of necroptosis. Here, serum MLKL levels were measured with the intent to assess its prognostic significance in acute intracerebral hemorrhage (ICH).
methodsA collective of 161 patients with acute primary supratentorial ICH and 73 controls were enlisted in this multicenter prospective cohort study. Serum MLKL levels were measured at admission in all patients, at study entry in all controls, and on post-ICH days 1, 3, 5, 7, 10, and 15 in 73 of all patients. Multivariate analyses were adopted to assess relationships between serum MLKL levels, severity, early neurological deterioration (END), poststroke 6-month modified Rankin Scale (mRS) scores, and poor prognosis (mRS scores of 3-6).
resultsPatients, relative to controls, had significantly promoted serum MLKL levels from admission until Day 15, with the peaking value at Day 3 (p < 0.001). Admission serum MLKL levels were independently correlated with National Institutes of Health Stroke Scale (NIHSS) scores (beta, 0.133; 95% confidence interval (CI), 0.088-0.178; p = 0.011), hematoma volume (beta, 0.051; 95%CI, 0.037-0.064; p = 0.001), and 6-month mRS scores (beta, 0.707; 95%CI, 0.487-0.927; p = 0.023), as well as independently predicted END (odds ratio, 1.902; 95%CI, 1.229-2.945; p = 0.014) and poor prognosis (odds ratio, 2.286; 95%CI, 1.324-3.946; p = 0.038). Admission serum MLKL levels were linearly connected to risks of poor prognosis (p > 0.05) and END (p > 0.05), had no interactions with age, gender, hypertension, and so forth (all p > 0.05), and possessed similar areas under the receiver operating characteristic curve to NIHSS scores and hematoma volume (all p > 0.05). The models integrating serum MLKL levels, NIHSS scores, and hematoma volume were graphically represented by nomogram and predicted END and poor prognosis with a good consistency under the calibration curve.
conclusionsSerum MLKL levels are markedly increased shortly following ICH, and may accurately mirror disease severity, and efficaciously anticipate END and six-month bad prognosis of patients, strengthening serum MLKL as a prognostic biomarker of good prospect in ICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.